The Experts below are selected from a list of 327 Experts worldwide ranked by ideXlab platform

Glenn J Jaffe - One of the best experts on this subject based on the ideXlab platform.

  • preventing relapse in non infectious uveitis affecting the posterior segment of the eye evaluating the 0 2 μg day Fluocinolone acetonide intravitreal implant iluvien
    Journal of Ophthalmic Inflammation and Infection, 2020
    Co-Authors: B Bodaghi, Glenn J Jaffe, Ramin Khoramnia, Quan Dong Nguyen, Carlos Pavesio
    Abstract:

    The current article is a short review of an Alimera Sciences-sponsored symposium held during The 15th International Ocular Inflammation Society Congress in Taiwan on the 14th November 2019 entitled, ‘Preventing relapse of non-infectious uveitis effecting the posterior segment of the eye – evaluating the 0.2 μg/day Fluocinolone acetonide intravitreal implant.’ The Fluocinolone acetonide intravitreal implant was approved in Europe for the prevention of relapse in recurrent non-infectious uveitis affecting the posterior segment of the eye and offers a systemic therapy-sparing treatment option by providing low daily dose of corticosteroid into the vitreous for up to 3 years. In the symposium, the presenters reported clinical outcomes from patients with non-infectious uveitis effecting the posterior segment of the eye to support the effectiveness and safety of the implant for up to 3 years in both randomised controlled trials and real-world practices. Data showed that over a 36 month period, treatment with the Fluocinolone acetonide intravitreal implant was associated with significantly fewer episodes of uveitic recurrence, a significantly longer time to uveitic recurrence, greater improvement in visual acuity, a lower need for adjunctive therapy, and an acceptable safety profile.

  • effect of a Fluocinolone acetonide insert on recurrence rates in noninfectious intermediate posterior or panuveitis three year results
    Ophthalmology, 2020
    Co-Authors: Glenn J Jaffe, Carlos Pavesio, Study Investigators
    Abstract:

    Purpose To examine the 36-month efficacy and safety of a 0.2 μg/day Fluocinolone acetonide insert (FAi) to treat noninfectious uveitis of the posterior segment (NIU-PS). Design Phase 3, prospective, double-masked, multicenter study ( clinicaltrials.gov , NCT01694186 ). Participants Adults (≥18 years old) with a diagnosis of NIU-PS in ≥1 eye for ≥1 year and ≥2 recurrences of uveitis requiring systemic corticosteroid, immunosuppressive treatment, or intraocular corticosteroids. Methods Participants were randomized 2:1 to FAi or sham (injection plus standard of care) treatment. Main Outcome Measures The primary outcome was the difference between the proportion of FAi-treated and sham-treated patients who had a uveitis recurrence. Secondary outcomes included time to first recurrence, number of recurrences, best-corrected visual acuity (BCVA) change from baseline, resolution of macular edema, and number of adjunctive treatments. Results One hundred twenty-nine participants (n = 87 FAi-treated; n = 42 sham-treated) were enrolled. Over 36 months of treatment, cumulative uveitis recurrences were significantly reduced with FAi compared with sham (65.5% vs. 97.6%, respectively; P Conclusions Fluocinolone acetonide insert–treated eyes had significantly reduced uveitis recurrence rates throughout the study duration, significantly increased recurrence-free durations, fewer recurrence episodes among those with recurrences, less adjunctive therapy, and an acceptable side-effect profile compared with sham-treated eyes.

  • spontaneous dislocation of Fluocinolone acetonide implant pellets from their suture struts
    American Journal of Ophthalmology, 2015
    Co-Authors: Sujit Itty, David Callanan, Racheal Jones, Paula E Pecen, Joseph N Martel, Glenn J Jaffe
    Abstract:

    Purpose To characterize spontaneous dislocation of the Fluocinolone acetonide sustained release implant (Retisert; Bausch & Lomb) drug pellet from its strut. Design Retrospective, observational case series. Methods The medical records of 224 patients in whom 407 Fluocinolone acetonide implants were placed by either of 2 surgeons between 1998 and 2012 were reviewed for drug pellet–suture strut separation, observed before surgery in clinic or occurring at the time of implant replacement. Results Seventeen (4.2%) of 407 drug pellets spontaneously dislocated away from the suture strut at a mean postimplantation time of 77.4 months (range, 33 to 132 months). The rate of spontaneous dislocation increased from 1 dislocation per 262 person years (95% confidence interval, 1 per 1269 to 1 per 89.6 person-years) before 60 months to 1 dislocation per 13.3 person-years (95% confidence interval, 1 per 24.4 to 1 per 7.9 person-years) afterward. Fourteen of 17 dislocated pellets were removed surgically. Of 77 exchanged Fluocinolone acetonide implants without dislocated pellets, 11 (14.2%) pellets had separated, but not dislocated away, from the strut; time to exchange of dislocated or dissociated pellets was significantly longer than time to exchange of intact Fluocinolone acetonide implants (70.5 vs 44.9 months; P Conclusions The Fluocinolone acetonide drug pellet can dislocate spontaneously from the suture strut as a late event that typically occurs after 3 years. Pellets also may be dissociated from the strut without dislocation, when separation occurs at the time of surgical replacement. Removal of the dislocated pellet can be achieved safely. Time was the major risk factor identified for both events.

  • pars plana vitrectomy Fluocinolone acetonide implantation and silicone oil infusion for the treatment of chronic refractory uveitic hypotony
    American Journal of Ophthalmology, 2011
    Co-Authors: Pouya Dayani, Sandra S Stinnett, Jessica H Chow, Glenn J Jaffe
    Abstract:

    Purpose To assess the feasibility and outcomes of combining Fluocinolone acetonide sustained drug delivery implant insertion, pars plana vitrectomy, and silicone oil infusion to treat patients with chronic, refractory ocular hypotony resulting from uveitis. Design Retrospective chart review. Methods A retrospective, institutional chart review was performed. Outcome measures included visual acuity, intraocular pressure, and adverse events. Results A total of 13 eyes of 11 patients were studied. All patients were women, had a mean age of 57 years (range, 26 to 73 years), and had a diagnosis of panuveitis. The mean duration of preoperative hypotony was 42 months (range, 11 to 108 months). Patients were followed up on average for 22 months (range, 9 to 46 months) after the combined surgical procedure. The mean preoperative visual acuity was 20/1000 (logarithm of the minimal angle of resolution, 1.7). At the 6- and 12-month visits, the mean visual acuity remained stable at 20/800 (logarithm of the minimal angle of resolution, 1.6; P = .74) and 20/600 ( P = .34), respectively. At baseline, the mean intraocular pressure (IOP) was 2.3 mm Hg. The average IOP was 5.9 mm Hg, 5.1 mm Hg, and 5.0 mm Hg at 6, 12, and 24 months after surgery, respectively. The increase in IOP relative to the baseline IOP was statistically significant at 6 and 12 months ( P = .027 and P = .004, respectively). The duration of preoperative hypotony inversely correlated with the IOP at 6 months ( P = .027). No intraoperative complications were encountered and the procedure was well tolerated. Conclusions Fluocinolone acetonide implantation combined with pars plana vitrectomy and silicone oil infusion is feasible and is well tolerated in the management of chronic, refractory ocular hypotony associated with uveitis.

  • combined Fluocinolone acetonide intravitreal insertion and glaucoma drainage device placement for chronic uveitis and glaucoma
    American Journal of Ophthalmology, 2010
    Co-Authors: Paula E Malone, Leon W Herndon, Kelly W Muir, Glenn J Jaffe
    Abstract:

    Purpose To determine whether a Fluocinolone acetonide sustained-release intravitreal drug delivery system can be implanted safely at the same time that a glaucoma drainage device is placed for eyes with uveitis and elevated intraocular pressure (IOP) receiving maximum tolerated IOP-lowering therapy. Design Retrospective, observational case series. Methods Subjects had chronic noninfectious intermediate or posterior uveitis and elevated IOP while receiving maximum tolerated medical therapy. Fluocinolone acetonide implantation and glaucoma tube shunt placement were performed in a single surgical session. The main outcome measures were inflammatory recurrences, visual acuity (VA), use of adjunctive anti-inflammatory therapy, IOP, and adverse events. Results Seven eyes of 5 patients were studied. The average number of recurrences 12 months before implantation was 3 episodes per eye; of the 3 eyes followed up for more than 30 months, none had an inflammatory recurrence within 30 months after implantation. The mean Snellen visual acuity 12 months after the combined surgery was 20/114, compared with 20/400 at baseline. Adjunctive steroid use decreased. Average IOP decreased from 27.3 mm Hg at baseline to 14.6 mm Hg 12 months after the combined surgery ( P = .019). Conclusions The favorable results observed in all eyes suggest that Fluocinolone acetonide implantation can be safely combined with glaucoma tube shunt placement in a single surgical session in eyes with uveitis and elevated IOP receiving maximum tolerated IOP-lowering therapy. Uveitis recurrences decreased, visual acuity improved, and IOP decreased. There were no adverse events during insertion of the Fluocinolone acetonide implant and placement of the glaucoma tube shunt.

Paul Ashton - One of the best experts on this subject based on the ideXlab platform.

  • long term follow up results of a pilot trial of a Fluocinolone acetonide implant to treat posterior uveitis
    Ophthalmology, 2005
    Co-Authors: Glenn J Jaffe, Rex M Mccallum, Brenda Branchaud, Cindy Skalak, Zuhal Butuner, Paul Ashton
    Abstract:

    Purpose To investigate the safety and efficacy of a Fluocinolone acetonide intravitreal implant in the treatment of noninfectious posterior uveitis. Design Noncomparative interventional case series, dose randomized, dose masked, prospective. Participants Thirty-six eyes of 32 patients with a history of recurrent noninfectious posterior uveitis. Methods Patients were randomized to receive either a 0.59-mg or a 2.1-mg Fluocinolone acetonide intravitreal implant. Patients were observed every 4 to 6 weeks for the first 3 months and then every 3 months thereafter. Main Outcome Measures Preoperative and postoperative ocular inflammation, visual acuity (VA), antiinflammatory medication use, and safety. Results Mean follow-up duration was 683±461 days (range, 204–1817). Mean baseline visual acuity for the device-implanted eyes was +1.1 logarithm of the minimum angle of resolution (logMAR) units (20/250), which improved significantly to +0.81 logMAR units (20/125) at 30 months ( P P P = 0.005). Filtering procedures were performed in 7 (19.4%) eyes. Four of the 8 phakic eyes, each of which had some level of cataract at device implantation, subsequently underwent cataract extraction. There were no device explantations or patients lost to follow-up during the investigation. Conclusion The Fluocinolone acetonide intravitreal implant effectively controlled intraocular inflammation in the studied population. Elevated IOP and cataracts that occurred in Fluocinolone device-implanted eyes were managed by standard means. The Fluocinolone acetonide sustained drug delivery implant seems to be promising in patients with posterior uveitis who do not respond to or are intolerant to conventional treatment.

  • Fluocinolone acetonide sustained drug delivery device to treat severe uveitis
    Ophthalmology, 2000
    Co-Authors: Glenn J Jaffe, Joshua Bennun, James P. Dunn, Paul Ashton
    Abstract:

    Abstract Purpose Uveitis is often a chronic disease requiring long-term medical therapy. In this report, we describe a pilot safety and efficacy trial of a novel sustained drug delivery system containing Fluocinolone acetonide to treat patients with severe uveitis. Design Prospective, noncomparative, interventional case series Participants Patients with severe uveitis. Methods Sustained drug delivery devices designed to release Fluocinolone acetonide for at least 2.5 years were implanted through the pars plana into the vitreous cavity of seven eyes of five patients. All patients had severe uveitis not well controlled with, or intolerant to, repeated periocular corticosteroid injections, systemic corticosteroids, nonsteroidal immunosuppressive agents, or a combination thereof at the time of device implantation. Before device implantation, patients underwent complete evaluation including history, ophthalmologic examination, fluorescein angiography, visual field testing, and electroretinography. After surgery, patients were reexamined at 1 week, 2 weeks, 4 weeks, and at 1- to 3-month intervals. Visual fields, electroretinograms, and fluorescein angiography were repeated at 3- to 6-month intervals. Main outcome measures Preoperative and postoperative visual acuity, ocular inflammation, anti-inflammatory medication use, and intraocular pressure. Results Patients had a diagnosis of Behcet's syndrome (two eyes), or idiopathic panuveitis (five eyes, including two with necrotizing retinitis, two with progressive chorioretinitis, and one with iridocyclitis and intermediate uveitis). Patients were observed an average of 10 months (range, 5–19 months). All eyes had stabilized or improved visual acuity after device implantation, and four of seven eyes had an improvement of three lines or more. The mean initial visual acuity, measured by Snellen chart, was 20/207, and the mean final visual acuity was 20/57 ( P = 0.02). After surgery, at the final visit, no eye had clinically detectable inflammation, and all seven eyes had a marked reduction in systemic, topical, and periocular anti-inflammatory medication use. Four eyes had increased intraocular pressure 6 weeks to 6 months after device implantation. Intraocular pressure has been controlled on topical medications. No patient experienced intraoperative complications. Conclusions A Fluocinolone acetonide sustained drug delivery device is a promising new therapy for the treatment of severe uveitis. Intraocular pressure must be carefully monitored long after device implantation. Based on these data, a randomized study of a larger group of patients is warranted.

  • safety and pharmacokinetics of an intraocular Fluocinolone acetonide sustained delivery device
    Investigative Ophthalmology & Visual Science, 2000
    Co-Authors: Glenn J Jaffe, Chang Hao Yang, Hong Guo, John P Denny, Cristiana Lima, Paul Ashton
    Abstract:

    PURPOSE To determine the safety and pharmacokinetics of an intraocular Fluocinolone acetonide sustained drug delivery device. METHODS Nonbiodegradable drug delivery devices containing 2 or 15 mg of a synthetic corticosteroid, Fluocinolone acetonide, were constructed. The long-term in vitro release rates of these devices were determined in protein-free buffer or buffer containing 50% plasma protein. Fifteen-milligram devices were also implanted into the vitreous cavities of rabbit eyes. Intravitreal drug levels, the amount of drug remaining in explanted devices, and the release rate of explanted devices were determined over a 1-year time period. Drug toxicity was assessed over this same time period by slit lamp examination, indirect ophthalmoscopy, electroretinography, and histologic examination. RESULTS The drug release rates for the 2-mg device, 1.9 +/- 0.25 microg/d, and for the 15-mg device, 2.2 +/- 0.6 microg/d, remained linear over the 6-month and 45-day testing period, respectively. The release rate increased by approximately 20% when devices were transferred from protein-free buffer to buffer that contained protein (P: < 0.0001). Vitreous levels remained fairly constant (0.10-0.21 microg/ml) over a 1-year period. No drug was present in the aqueous humor during this time period. Based on the device release rates, the predicted life span of the 2- and 15-mg devices are 2.7 and 18.6 years, respectively. There was no evidence of drug toxicity by clinical examination, electroretinography, or histologic examination. CONCLUSIONS It is feasible to construct a nontoxic Fluocinolone acetonide drug delivery device that reproducibly releases Fluocinolone acetonide in a linear manner over an extended period. These devices show great promise in the treatment of ocular diseases such as uveitis, which are often managed with chronic corticosteroid therapy.

Quan Dong Nguyen - One of the best experts on this subject based on the ideXlab platform.

  • preventing relapse in non infectious uveitis affecting the posterior segment of the eye evaluating the 0 2 μg day Fluocinolone acetonide intravitreal implant iluvien
    Journal of Ophthalmic Inflammation and Infection, 2020
    Co-Authors: B Bodaghi, Glenn J Jaffe, Ramin Khoramnia, Quan Dong Nguyen, Carlos Pavesio
    Abstract:

    The current article is a short review of an Alimera Sciences-sponsored symposium held during The 15th International Ocular Inflammation Society Congress in Taiwan on the 14th November 2019 entitled, ‘Preventing relapse of non-infectious uveitis effecting the posterior segment of the eye – evaluating the 0.2 μg/day Fluocinolone acetonide intravitreal implant.’ The Fluocinolone acetonide intravitreal implant was approved in Europe for the prevention of relapse in recurrent non-infectious uveitis affecting the posterior segment of the eye and offers a systemic therapy-sparing treatment option by providing low daily dose of corticosteroid into the vitreous for up to 3 years. In the symposium, the presenters reported clinical outcomes from patients with non-infectious uveitis effecting the posterior segment of the eye to support the effectiveness and safety of the implant for up to 3 years in both randomised controlled trials and real-world practices. Data showed that over a 36 month period, treatment with the Fluocinolone acetonide intravitreal implant was associated with significantly fewer episodes of uveitic recurrence, a significantly longer time to uveitic recurrence, greater improvement in visual acuity, a lower need for adjunctive therapy, and an acceptable safety profile.

  • Fluocinolone acetonide implant for vogt koyanagi harada disease three year outcomes of efficacy and safety
    Retina-the Journal of Retinal and Vitreous Diseases, 2016
    Co-Authors: Jang Won Heo, Bumjoo Cho, Debra A Goldstein, Yasir J Sepah, Quan Dong Nguyen
    Abstract:

    PURPOSE To investigate the efficacy and safety of Fluocinolone acetonide intravitreal implant in patients with Vogt-Koyanagi-Harada disease. METHODS A post hoc, subgroup analysis on patients with Vogt-Koyanagi-Harada was performed using data sets from two multicenter randomized trials on Fluocinolone acetonide implant. Each subject received Fluocinolone acetonide implantation in one eye and standard-of-care treatment in the fellow eye and was followed for 3 years. RESULTS Thirty patients were included with the mean age of 38.5 years. The cumulative rate of uveitis recurrence for 3 years was significantly reduced in implanted eyes compared with fellow eyes (33 vs. 87%; P < 0.001). The reduction of daily corticosteroid dose was well maintained (12.8 mg before implantation vs. 3.7 mg after implantation; P = 0.001), but final vision was similar to preoperative vision in the implanted eyes (P = 0.082) and in the fellow eyes (P = 0.187). Postoperative elevation of intraocular pressure was more frequent in the implanted eyes than in the fellow eyes (70 vs. 20%; P < 0.001). Cataract progression occurred in all phakic implanted eyes. CONCLUSION Fluocinolone acetonide intravitreal implant reduced uveitis recurrence rate and the dosage of systemic corticosteroid and immunosuppressant requirement in patients with Vogt-Koyanagi-Harada. However, cataract and intraocular pressure elevation developed frequently.

  • postoperative outcomes after Fluocinolone acetonide implant surgery in patients with birdshot chorioretinitis and other types of posterior and panuveitis
    Retina-the Journal of Retinal and Vitreous Diseases, 2013
    Co-Authors: Bryn M Burkholder, James P. Dunn, Quan Dong Nguyen, Jiangxia Wang, Jennifer E Thorne
    Abstract:

    Purpose To evaluate outcomes following placement of Fluocinolone acetonide (FA) implants in eyes with Birdshot chorioretinitis (BSCR) and to compare these outcomes with eyes with posterior and panuveitis.

  • aqueous levels of Fluocinolone acetonide after administration of Fluocinolone acetonide inserts or Fluocinolone acetonide implants
    Ophthalmology, 2013
    Co-Authors: Peter A Campochiaro, Thomas A Ciulla, Quan Dong Nguyen, Gulnar Hafiz, Steven M Bloom, David M Brown, Miguel Busquets, Leonard Feiner, Nelson R Sabates, Kathleen Billman
    Abstract:

    Purpose To compare aqueous levels of Fluocinolone acetonide (FAc) after administration of FAc inserts or FAc implants (Retisert; Bausch & Lomb, Rochester, NY). Design Comparison of pharmacokinetics from 2 prospective, interventional, clinical trials. Participants Thirty-seven patients with diabetic macular edema (DME) (Fluocinolone Acetonide in Human Aqueous [FAMOUS] Study, C-01-06-002) and 7 patients with uveitis (NA-00019318). Methods Aqueous FAc was measured after administration of FAc implants or 0.2 μg/day (low dose, ILUVIEN; Alimera Sciences Inc., Alpharetta, GA) or 0.5 μg/day (high dose) FAc inserts. Main Outcome Measures The primary end point was aqueous levels of FAc. Results At 1 month after administration for subjects who received 1 treatment, mean aqueous FAc levels were 2.17 (low dose) and 3.03 ng/ml (high dose) for FAc inserts and 6.12 ng/ml for FAc implants with maximum levels of 3.83, 6.66, and 13.50 ng/ml, respectively. At 3 months, mean FAc levels were 1.76, 2.15, and 6.12 ng/ml, respectively. Between 6 and 36 months after low-dose inserts, aqueous levels of FAc were remarkably stable, ranging from 1.18 to 0.45 ng/ml. After high-dose inserts, mean FAc levels were stable between 6 and 24 months, ranging from 1.50 to 0.84 ng/ml and then decreasing to 0.35 ng/ml at 30 months and 0.15 ng/ml at 36 months. In implant-containing eyes, mean FAc levels remained >6 ng/ml through 15 months, the last time point with measurements from at least 6 eyes. Conclusions Low- and high-dose FAc inserts both provide stable long-term release of FAc with comparable peak levels in the aqueous: slightly >2 ng/ml for approximately 3 months followed by steady-state levels between 1.0 and 0.5 ng/ml through 36 months for low-dose inserts versus levels between 1.5 and 1.1 ng/ml through 24 months for high-dose inserts. Steady-state aqueous levels after FAc implants were >6 ng/ml. These results provide new insights that aid in the interpretation of efficacy trials and indicate that there is a dose effect for steroid-induced ocular hypertension. In susceptible patients, prolonged aqueous levels of FAc >1 ng/ml moderately increased the risk of glaucoma and levels >6 ng/ml posed a markedly increase risk. Financial Disclosure(s) Proprietary or commercial disclosure may be found after the references.

  • post cataract outcomes in patients with noninfectious posterior uveitis treated with the Fluocinolone acetonide intravitreal implant
    Clinical Ophthalmology, 2012
    Co-Authors: John D Sheppard, Quan Dong Nguyen, Dale W Usner, Timothy L Comstock
    Abstract:

    Purpose To describe visual acuity (VA) and inflammation following cataract surgery in eyes with noninfectious posterior uveitis (NIPU) that were being treated with a Fluocinolone acetonide (FA) intravitreal implant compared with those that were not.

Peter K Kaiser - One of the best experts on this subject based on the ideXlab platform.

  • evaluation of Fluocinolone acetonide sustained release implant retisert dissociation during implant removal and exchange surgery
    American Journal of Ophthalmology, 2012
    Co-Authors: Benjamin P Nicholson, Rishi P Singh, Jonathan E Sears, Careen Y Lowder, Peter K Kaiser
    Abstract:

    Purpose To characterize the phenomenon of dissociation of the 2 components of the sustained-release Fluocinolone acetonide implant (Retisert; Bausch & Lomb) during removal or exchange procedures, or both, and to evaluate outcomes after these events. Design Retrospective, observational case series. Methods Retrospective review of 27 consecutive sustained-release Fluocinolone acetonide implant (Retisert) exchanges or removals between 2001 and 2010 at the Cole Eye Institute. All patients had received the implant as treatment for noninfectious uveitis. Preoperative and postoperative characteristics were analyzed, and operative reports were reviewed to characterize the effects of intraoperative implant dissociation. Results Twenty-seven sustained-release Fluocinolone acetonide implant (Retisert) exchange or removal surgeries were performed by 3 surgeons in 20 eyes of 19 patients. Of these 27 procedures, dissociation of the implant strut from the drug-containing cup occurred in 11 eyes (40.7%). Retrieval of the dislocated cup led to intraoperative complications, including posterior retinal tear (n = 1) and limited suprachoroidal hemorrhage (n = 1). The length of time that the implant resided in the eye correlated significantly with cup dissociation. Dissociated implants resided a mean of 47.4 months, whereas intact implants resided a mean of 32.5 months ( P = .0032). There was no long-term or short-term vision loss attributed to intraoperative implant dissociation. Conclusions Sustained-release Fluocinolone acetonide implant (Retisert) dissociation is a common occurrence in exchange or removal procedures, or both. The longer an implant resided in the eye, the greater the tendency toward dissociation. Preparation for this complication should be contemplated in any implant removal or exchange procedure.

  • scleral thickness following Fluocinolone acetonide implant retisert
    Ocular Immunology and Inflammation, 2010
    Co-Authors: Mehran Taban, Careen Y Lowder, Alexandre A C M Ventura, Sumit Sharma, Benjamin Nutter, Brandy C Hayden, William J Dupps, Peter K Kaiser
    Abstract:

    Purpose: To evaluate whether intravitreal Fluocinolone acetonide (FA) implantation (Retisert) leads to scleral thinning.Methods: Scleral thickness was measured at the pars plana region (4 quadrants) with anterior segment OCT (Visante) in FA implanted eyes (18) with noninfectious posterior uveitis in comparison to eyes with prior vitrectomy (8), and normal eyes without prior surgery (30).Results: Mean scleral thickness in normal (nonsurgical) eyes was 0.99/0.93/0.88/0.86, and 0.92 mm in the inferonasal/inferotemporal/superotemporal/superonasal quadrants, and overall, respectively. Sclera was thinner in each quadrant of the FA implanted eyes compared to the fellow or nonsurgical eyes, although none reached statistical significance, as the differences were small. However, a few FA implanted eyes demonstrated more dramatic scleral thinning than others.Conclusions: FA implant appears to lead to statistically nonsignificant scleral thinning overall with few exceptions. Clinicians should be aware of potential sc...

  • outcome of Fluocinolone acetonide implant retisert reimplantation for chronic noninfectious posterior uveitis
    Retina-the Journal of Retinal and Vitreous Diseases, 2008
    Co-Authors: Mehran Taban, Careen Y Lowder, Peter K Kaiser
    Abstract:

    Purpose:To evaluate outcomes of repeat intravitreal Fluocinolone acetonide implant (Retisert™) in patients with chronic noninfectious posterior uveitis.Methods:Retrospective, observational case series of 10 eyes (10 patients) with recurrent noninfectious posterior uveitis who underwent a second fluo

  • cytomegalovirus retinitis after Fluocinolone acetonide retisert implant
    American Journal of Ophthalmology, 2007
    Co-Authors: Rafael Ufretvincenty, Rishi P Singh, Careen Y Lowder, Peter K Kaiser
    Abstract:

    Purpose To report a case of cytomegalovirus (CMV) retinitis after placement of a Fluocinolone acetonide (Retisert™) implant. Design Interventional case report. Methods Retrospective chart review. Results A 65-year-old man with a history of Adamantiades-Behcet disease and bilateral recurrent uveitis that was unresponsive to systemic corticosteroid-sparing immunosuppressive therapy developed clinical evidence of CMV retinitis after receiving his second intravitreal Retisert™ implant in the left eye, while on no systemic immunosuppression. He did not develop CMV retinitis in the right eye despite multiple intraocular and periocular steroid injections. The patient responded well to intravitreal foscarnet followed by placement of an intravitreal ganciclovir implant. Conclusions Ophthalmologists should be aware of the potential risk for development of CMV retinitis after local ocular immunosuppressive therapy.

Timothy L Comstock - One of the best experts on this subject based on the ideXlab platform.